RU2011102743A - Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения - Google Patents
Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения Download PDFInfo
- Publication number
- RU2011102743A RU2011102743A RU2011102743/15A RU2011102743A RU2011102743A RU 2011102743 A RU2011102743 A RU 2011102743A RU 2011102743/15 A RU2011102743/15 A RU 2011102743/15A RU 2011102743 A RU2011102743 A RU 2011102743A RU 2011102743 A RU2011102743 A RU 2011102743A
- Authority
- RU
- Russia
- Prior art keywords
- determinants
- subject
- tumor
- sample
- level
- Prior art date
Links
- 206010027476 Metastases Diseases 0.000 title claims abstract 6
- 230000009401 metastasis Effects 0.000 title claims abstract 6
- 238000000034 method Methods 0.000 claims abstract 50
- 206010028980 Neoplasm Diseases 0.000 claims abstract 27
- 206010061289 metastatic neoplasm Diseases 0.000 claims abstract 13
- 238000001574 biopsy Methods 0.000 claims abstract 10
- 238000005259 measurement Methods 0.000 claims abstract 5
- 230000000984 immunochemical effect Effects 0.000 claims abstract 4
- 108090000790 Enzymes Proteins 0.000 claims abstract 2
- 102000004190 Enzymes Human genes 0.000 claims abstract 2
- 238000003018 immunoassay Methods 0.000 claims abstract 2
- 238000010185 immunofluorescence analysis Methods 0.000 claims abstract 2
- 238000003127 radioimmunoassay Methods 0.000 claims abstract 2
- 230000000306 recurrent effect Effects 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 238000011269 treatment regimen Methods 0.000 claims 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 2
- 206010061309 Neoplasm progression Diseases 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 238000009098 adjuvant therapy Methods 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 230000008238 biochemical pathway Effects 0.000 claims 2
- 239000000090 biomarker Substances 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 230000012292 cell migration Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 210000002744 extracellular matrix Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 230000005751 tumor progression Effects 0.000 claims 2
- 108091023037 Aptamer Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000012360 testing method Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7593308P | 2008-06-26 | 2008-06-26 | |
| US61/075,933 | 2008-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2011102743A true RU2011102743A (ru) | 2012-08-10 |
Family
ID=41445345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2011102743/15A RU2011102743A (ru) | 2008-06-26 | 2009-06-26 | Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110182881A1 (enExample) |
| EP (1) | EP2307886A2 (enExample) |
| JP (1) | JP2011526693A (enExample) |
| KR (1) | KR20110036056A (enExample) |
| CN (1) | CN102132160A (enExample) |
| AU (1) | AU2009262022A1 (enExample) |
| BR (1) | BRPI0914734A2 (enExample) |
| CA (1) | CA2728674A1 (enExample) |
| IL (1) | IL210245A0 (enExample) |
| MX (1) | MX2010014280A (enExample) |
| NZ (1) | NZ590385A (enExample) |
| RU (1) | RU2011102743A (enExample) |
| WO (1) | WO2009158620A2 (enExample) |
| ZA (1) | ZA201100225B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| US20100248269A1 (en) * | 2009-03-30 | 2010-09-30 | New York Blood Center | Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer |
| AU2011216404B2 (en) | 2010-02-17 | 2016-04-07 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2013533960A (ja) | 2010-06-01 | 2013-08-29 | トドス メディカル リミテッド | がんの診断 |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2012030840A2 (en) | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| US8880457B2 (en) * | 2010-11-05 | 2014-11-04 | Allegheny-Singer Research Institute | Method and system for recommending a decision based on combined entity modeling |
| US9719937B2 (en) | 2011-05-11 | 2017-08-01 | Todos Medical Ltd. | Diagnosis of cancer |
| US20140302042A1 (en) * | 2011-07-01 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
| CN103842813B (zh) * | 2011-09-06 | 2018-04-17 | 贝克顿·迪金森公司 | 用于对样品中的稀少目标细胞进行细胞计数检测的方法和组合物 |
| WO2014036470A1 (en) | 2012-08-31 | 2014-03-06 | Sloan-Kettering Institute For Cancer Research | Particles, methods and uses thereof |
| JP6164678B2 (ja) * | 2012-10-23 | 2017-07-19 | 国立研究開発法人科学技術振興機構 | ネットワークエントロピーに基づく生体の状態遷移の予兆の検出を支援する検出装置、検出方法及び検出プログラム |
| WO2014078700A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| JP6465811B2 (ja) | 2012-12-19 | 2019-02-06 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 多様式の粒子、方法およびその使用 |
| AU2014218867B2 (en) | 2013-02-20 | 2018-11-08 | Sloan-Kettering Institute For Cancer Research | Wide field raman imaging apparatus and associated methods |
| EP4265740A3 (en) * | 2013-03-14 | 2024-04-24 | Castle Biosciences, Inc. | Methods for predicting risk of metastasis in cutaneous melanoma |
| EP3004870B1 (en) | 2013-05-28 | 2019-01-02 | Todos Medical Ltd. | Differential diagnosis of benign tumors |
| GB201317609D0 (en) | 2013-10-04 | 2013-11-20 | Cancer Rec Tech Ltd | Inhibitor compounds |
| US10912947B2 (en) | 2014-03-04 | 2021-02-09 | Memorial Sloan Kettering Cancer Center | Systems and methods for treatment of disease via application of mechanical force by controlled rotation of nanoparticles inside cells |
| US20150252434A1 (en) * | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| WO2016018896A1 (en) | 2014-07-28 | 2016-02-04 | Memorial Sloan Kettering Cancer Center | Metal(loid) chalcogen nanoparticles as universal binders for medical isotopes |
| US11009467B2 (en) * | 2015-02-17 | 2021-05-18 | Siemens Healthcare Diagnostics Inc. | Model-based methods and apparatus for classifying an interferent in specimens |
| GB201505658D0 (en) | 2015-04-01 | 2015-05-13 | Cancer Rec Tech Ltd | Inhibitor compounds |
| WO2017004301A1 (en) | 2015-07-01 | 2017-01-05 | Memorial Sloan Kettering Cancer Center | Anisotropic particles, methods and uses thereof |
| GB201617103D0 (en) | 2016-10-07 | 2016-11-23 | Cancer Research Technology Limited | Compound |
| CN109844140A (zh) * | 2016-10-28 | 2019-06-04 | 茂英基因科技股份有限公司 | 辨识转移性肿瘤的原发位置的方法及系统 |
| US20200224277A1 (en) * | 2017-07-17 | 2020-07-16 | Mao Ying Genetech Inc. | Cell type identification method and system thereof |
| CN109932510B (zh) * | 2017-12-18 | 2022-07-12 | 天津云检医学检验所有限公司 | 一种宫颈癌生物标志物及其检测试剂盒 |
| JP7580210B2 (ja) * | 2020-06-15 | 2024-11-11 | 三菱重工業株式会社 | 予兆判定装置、予兆判定方法及びプログラム |
| CA3233047A1 (en) * | 2021-09-20 | 2023-03-23 | Droplet Biosciences, Inc. | Methods for disease assessment using drain fluid |
| AU2022405276A1 (en) * | 2021-12-08 | 2024-07-11 | Mayo Foundation For Medical Education And Research | Assessing and treating melanoma |
| CN116204890B (zh) * | 2023-04-28 | 2023-07-21 | 浙江鹏信信息科技股份有限公司 | 一种自适应增强人工智能算法安全的算法组件库 |
| CN117171678B (zh) * | 2023-11-02 | 2024-01-12 | 北京建工环境修复股份有限公司 | 一种微生物修复过程中土壤微生物菌群调控方法及系统 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1178414A (en) * | 1978-02-08 | 1984-11-27 | Toyo Boseki Kabushiki Kaisha (Trading Under The Name Of Toyobo Co., Ltd.) | Packaging material having excellent seal packaging property |
| US4275149A (en) * | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4659678A (en) * | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
| US4727022A (en) * | 1984-03-14 | 1988-02-23 | Syntex (U.S.A.) Inc. | Methods for modulating ligand-receptor interactions and their application |
| US5018067A (en) * | 1987-01-12 | 1991-05-21 | Iameter Incorporated | Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure grouping and severity of illness indicators |
| US5744101A (en) * | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US20020038227A1 (en) * | 2000-02-25 | 2002-03-28 | Fey Christopher T. | Method for centralized health data management |
| WO2003025141A2 (en) * | 2001-09-19 | 2003-03-27 | Intergenetics Incorporated | Genetic analysis for stratification of cancer risk |
| US20040122296A1 (en) * | 2002-12-18 | 2004-06-24 | John Hatlestad | Advanced patient management for triaging health-related data |
| US7468032B2 (en) * | 2002-12-18 | 2008-12-23 | Cardiac Pacemakers, Inc. | Advanced patient management for identifying, displaying and assisting with correlating health-related data |
| US20030232398A1 (en) * | 2002-03-28 | 2003-12-18 | Macmurray James P. | Use of ROC plots of genetic risk factor to predict risk of sporadic breast cancer |
| US20050208500A1 (en) * | 2003-03-04 | 2005-09-22 | Erlander Mark G | Signatures of ER status in breast cancer |
| EP1751306A1 (en) * | 2004-04-30 | 2007-02-14 | Yale University | Methods and compositions for cancer diagnosis |
| JP5184087B2 (ja) * | 2004-09-22 | 2013-04-17 | トリパス イメージング， インコーポレイテッド | ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品 |
| WO2007059313A1 (en) * | 2005-11-16 | 2007-05-24 | Children's Medical Center Corporation | Method to assess breast cancer risk |
| US8445198B2 (en) * | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| US20090069196A1 (en) * | 2006-03-22 | 2009-03-12 | Mathias Gehrmann | Prediction of Breast Cancer Response to Chemotherapy |
| NZ575090A (en) * | 2006-09-06 | 2012-02-24 | Univ California | Molecular diagnosis and classification of malignant melanoma using RGS1, ARPC2, FN1, SPP1 and WNT-2 polypeptide markers |
| RU2009114745A (ru) * | 2006-09-19 | 2010-10-27 | Новартис АГ (CH) | Биомаркеры, предназначенные для выявления направленной модуляции, эффективности ингибиторов raf, применения с целью диагностики и/или прогнозирования |
| EP2092075A2 (en) * | 2006-11-06 | 2009-08-26 | Source Precision Medicine, Inc. | Gene expression profiling for identification, monitoring and treatment of melanoma |
| EP2155897A2 (en) * | 2007-03-30 | 2010-02-24 | Source Precision Medicine, Inc. d/b/a Source MDX. | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| US20110160072A1 (en) * | 2007-10-23 | 2011-06-30 | Clinical Genomics Pty. Ltd. | Method of diagnosing neoplasms |
| NZ587903A (en) * | 2008-02-14 | 2013-05-31 | Decode Genetics Ehf | Susceptibility for lung cancer using the polymorphic marker rs1051730 |
| WO2009124251A1 (en) * | 2008-04-03 | 2009-10-08 | Sloan-Kettering Institute For Cancer Research | Gene signatures for the prognosis of cancer |
| CA2724348A1 (en) * | 2008-05-15 | 2009-11-19 | University Of Southern California | Genotype and expression analysis for use in predicting outcome and therapy selection |
| WO2011063274A2 (en) * | 2009-11-23 | 2011-05-26 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
-
2009
- 2009-06-26 RU RU2011102743/15A patent/RU2011102743A/ru not_active Application Discontinuation
- 2009-06-26 MX MX2010014280A patent/MX2010014280A/es not_active Application Discontinuation
- 2009-06-26 KR KR1020117001619A patent/KR20110036056A/ko not_active Withdrawn
- 2009-06-26 JP JP2011516713A patent/JP2011526693A/ja not_active Withdrawn
- 2009-06-26 WO PCT/US2009/048862 patent/WO2009158620A2/en not_active Ceased
- 2009-06-26 EP EP09771151A patent/EP2307886A2/en not_active Withdrawn
- 2009-06-26 CN CN2009801331437A patent/CN102132160A/zh active Pending
- 2009-06-26 BR BRPI0914734A patent/BRPI0914734A2/pt not_active IP Right Cessation
- 2009-06-26 AU AU2009262022A patent/AU2009262022A1/en not_active Abandoned
- 2009-06-26 CA CA2728674A patent/CA2728674A1/en not_active Abandoned
- 2009-06-26 NZ NZ590385A patent/NZ590385A/xx not_active IP Right Cessation
- 2009-06-26 US US13/001,203 patent/US20110182881A1/en not_active Abandoned
-
2010
- 2010-12-23 IL IL210245A patent/IL210245A0/en unknown
-
2011
- 2011-01-07 ZA ZA2011/00225A patent/ZA201100225B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2307886A2 (en) | 2011-04-13 |
| MX2010014280A (es) | 2011-05-23 |
| KR20110036056A (ko) | 2011-04-06 |
| JP2011526693A (ja) | 2011-10-13 |
| WO2009158620A2 (en) | 2009-12-30 |
| CA2728674A1 (en) | 2009-12-30 |
| BRPI0914734A2 (pt) | 2015-10-20 |
| IL210245A0 (en) | 2011-03-31 |
| ZA201100225B (en) | 2011-10-26 |
| US20110182881A1 (en) | 2011-07-28 |
| WO2009158620A3 (en) | 2010-06-03 |
| NZ590385A (en) | 2012-11-30 |
| AU2009262022A1 (en) | 2009-12-30 |
| CN102132160A (zh) | 2011-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2011102743A (ru) | Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения | |
| JP2011526693A5 (enExample) | ||
| Kim et al. | Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression | |
| Davies et al. | Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer | |
| JP2011528442A5 (enExample) | ||
| KR20100072283A (ko) | 환자의 유전자-베이스 알고리즘적 암 예후 및 임상적 결과 | |
| JP5747419B2 (ja) | 致死性細胞を検出する方法および組成物ならびにその使用 | |
| Guzzo et al. | Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance | |
| Mastrosimini et al. | Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors | |
| Hacking et al. | Potential pitfalls in diagnostic digital image analysis: experience with Ki-67 and PHH3 in gastrointestinal neuroendocrine tumors | |
| JP2008292424A (ja) | 腫瘍の検出方法 | |
| Wen et al. | Predictive value of molecular subtyping for locoregional recurrence in early-stage breast cancer with N1 without postmastectomy radiotherapy | |
| Miyashita et al. | Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates | |
| Zhao et al. | Clinical significance of Smac and survivin expression in breast cancer patients treated with anthracycline‑based neoadjuvant chemotherapy | |
| Takuwa et al. | Characteristic immunophenotype of solid subtype component in lung adenocarcinoma | |
| RU2383339C1 (ru) | Способ прогнозирования эффективности неоадъювантной химиотерапии при местнораспространенном раке яичников | |
| Tay et al. | Using computer assisted image analysis to determine the optimal Ki67 threshold for predicting outcome of invasive breast cancer | |
| AU2016359685B2 (en) | Methods of predicting progression of Barrett's esophagus | |
| Endo et al. | High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer | |
| US7951544B1 (en) | Method for determining the prognosis of cancer patients by measuring levels of bag expression | |
| Nathanson et al. | Her-2/neu expression in primary breast cancer with sentinel lymph node metastasis | |
| Thompson et al. | The history and future of melanoma staging | |
| Han | ER, PR and HER2 testing in breast cancer | |
| Billis et al. | Prostate total tumor extent versus index tumor extent—which is predictive of biochemical recurrence following radical prostatectomy? | |
| Schindlbeck et al. | Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20120627 |